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Abstract 
A simple, precise, sensitive and reproducible stability indicating Reverse Phase High Performance 
Liquid Chromatographic (RP-HPLC) method for determination of Azithromycin and Ofloxacin in tablet dosage 
form was developed. Chromatographic separation was achieved on Hypersil-Keystone RP C18 (250 × 4.6 mm, 
5µm) column maintained at 30 ºC eluted with mobile phase at flow rate of 1.2 ml/min. The mobile phase 
consists of Buffer (0.02 M potassium dihydrogenphosphate): methanol: acetonitrile in the ratio 65:25:10 v/v at 
pH maintained at 3.2 with OPA was used and the determination was carried out at 285 nm. The retention time 
for Azithromycin and Ofloxacin were 9.7 min and 5.01 respectively. The linearity was found in the range of 
5‒50 μg/ml for Azithromycin and 4‒40 μg/ml for Ofloxacin. In stability studies the drugs were well separated 
from degradation products. The degradation was studied in the individual standard drugs, their mixture and 
formulation which gave the idea about the orgin of the degradant products. The analytical method was validated 
as per ICH guideline for linearity, accuracy, precision, and specificity, limit of detection, limit of quantification, 
stability in analytical solution etc. and method can be extended to the analysis of Azithromycin and Ofloxacin in 
tablet formulations.  
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1.  Introduction 
Azithromycin (AZI) is a (2R,3S, 4R, 5R, 8R, 
10R, 11R, 12S, 13S,14S)-13-[(2,6-Dideoxy-3-C-
methyl-3-O-methyl-α-L- ribo-hexopyranosyl)oxy] -2-
ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,-14 
heptamethyl-11-[[3,4,6- trideoxy-3-(dimethylamino) 
β-D-xylohexopyranosyl]oxy]-1-oxa-6-
azacyclopentadecan-15- one is a semi-synthetic 
macrolide antibiotic related to Erythromycin. It 
differs chemically from erythromycin in that a 
methyl-substituted nitrogen atom is incorporated into 
the lactone ring. Macrolide antibiotics are a 
bacteriostatic agent that inhibits protein synthesis by 
binding reversibly to 50S ribosomal subunits of 
sensitive microorganisms, at or very near the sites 
that binds chloramphenicol (Figure 1). It is used in 
the treatment of S. pneumonia, Community-acquired 
pneumonia due to C. pneumoniae, Pharyngitis or 
tonsillitis, skin and skin structure infections. 
Ofloxacin (OFL) is a broad spectrum fluorinated 
quinolones antibacterial with chemical name 9-
Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-
piperazinyl)-7-oxo-7H- pyridol[1,2,3-de]-1,4 
benzoxazine -6-carboxylic acid (Figure 2). It is used 
in the treatment of respiratory tract infections, 
pharyngitis, community-acquired pneumonia, mild to 
moderate bacterial exacerbation, sexually transmitted 
diseases, acute and uncomplicated urethral and 
cervical gonorrhea, urethritis, complicated urinary 
tract infections, prostatitis[1-2].  
 
Figure 1: Structure of Azithromycin 
 
 
 
Figure 2: Structure of Ofloxacin 
 
   Literature survey reveals that there are few 
reported methods to determine AZI[3-8] and OFL[9-
12] alone in dosage forms by spectrometry and 
HPLC. Few methods are also available in 
combination with other drugs[13-22] in dosage forms 
by spectrometry and HPLC, but no HPLC method is 
available for the   simultaneous estimation of AZI 
and OFL in its dosage form. Therefore the purpose of 
this study is to develop stability indicating HPLC 
method for the simultaneous estimation of AZI and 
OFL in tablet dosage form. 
 
2.0 Materials and Methods 
2.1 Chemicals and Reagents 
AZI and OFL standards were obtained as a 
gift samples from Alkem Laboratories, Mumbai. 
Methanol and acetonitrile of HPLC grade (E. Merck) 
and potassium dihydrogenphosphate of AR grade 
(S.D. Fine Chemicals Ltd.) was purchased from local 
supplier. Milli Q water was used.  All the other 
reagents were of analytical grade. Marketed 
formulation Zithium-O (Alkem Laboratories Limited, 
Mumbai, India) was purchased from local pharmacy. 
2.2 HPLC instruments and analytical conditions 
The separation was carried out on HPLC 
(Waters 2998 with PDA detector), Waters 600 
controller (water’s 486 UV- visible tunable 
absorbance detector) were used to develop and 
validate the method. The chromatographic separation 
was carried out by using (Hypersil-keystone RP C18 
250 × 4.6 mm, 5µm) column, maintained at 30ºC. 
Data acquisition was done by using Data ace 
software and Empower 2 software. 
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2.3 Preparation of Mobile phase and Diluent  
The mobile phase consisting of buffer (0.02 
M potassium dihydrogenphosphate): methanol: 
acetonitrile (pH 3.2 adjusted with orthophosphoric 
acid) was filtered through 0.45μ membrane filter 
before use, degassed and was pumped from the 
solvent reservoir in the ratio of 65:25:10 v/v at a flow 
rate of 1.2 ml/min. The detection was monitored at 
285 nm and the run time was 25 min. The volume of 
injection loop was 10μl.  
2.4 Preparation of standard and sample 
(Azithromycin 500 mg + Ofloxacin 400 mg) 
solutions 
Accurately weighed about 500.0 mg of AZI 
and 400.0 mg of OFL working standards and 
transferred into separate 100 ml volumetric flasks 
containing 50 ml of diluent and dissolved by 
sonication. The volume was made up to 100 ml with 
diluent (5000 µg/ml and 4000 µg/ml of AZI and OFL 
respectively- stock A). Solutions were further 
appropriately diluted to get concentration of 10 µg/ml 
of AZI and 8 µg/ml of OFL in separate volumetric 
flask. Ten tablets of Zithium-O were accurately 
weighed and crushed to fine powder. Accurately 
weighed powder sample (1231mg) equivalent to 500 
mg of AZI (400 mg of OFL) was transferred into 100 
ml volumetric flask and dissolved by sonication for 
25 min with intermittent shaking. The filtered 
solution was further diluted to get the concentration 
10 µg/ ml of AZI (8 µg/ml of OFL). 
2.5 Method Development and Validation[23-24] 
During mobile phase optimization Buffer: 
methanol: acetonitrile in the ratio of 65:25:10 at 
λmax285 nm was found to be satisfactory for both 
drugs. After mobile phase selection, effect of pH and 
flow rate was studied on resolution of peaks of both 
the drugs from each other. It was found that pH 3.2 
(adjusted with OPA) and flow rate1.2 ml/min was 
suitable for both drugs. The method was validated for 
the parameters such as system suitability, selectivity, 
linearity and range, precision (interday and intraday), 
accuracy, robustness, ruggedness limit of quantitation 
(LOQ) and limit of detection (LOD).  
For the system suitability study, the standard 
solutions containing 10 µg/ml of AZI and 8 µg/ml of 
OFL were prepared and the column efficiency, 
resolution and peak asymmetry was calculated. The 
method specificity was assessed by comparing the 
chromatograms obtained from blank (mobile phase), 
chromatograms of single drug with the 
chromatograms of sample. The precision of the 
method was established by carrying out method 
precision, system precision, intraday and interday 
analysis and relative standard deviation (%RSD) was 
calculated. Method precision and system precision 
was determined by injecting the sample and standard 
solution containing the mixture of 10 µg/ml of AZI 
and 8 µg/ml of OFL (six replicates) into HPLC 
system. The intraday precision was studied by 
performing analysis at regular interval in a day at 
three different concentration levels (10, 20, 30 µg/ml 
for AZI and 8, 16, 24 µg/ml for OFL), while interday 
precision was performed on three different days (day 
1, 2, and 3). The accuracy of the method was 
determined by performing the recovery study by 
addition of standard drug to the preanalyzed sample 
at three different levels 80 %, 100 % and 120 % and 
average percentage recovery was determined. To 
determine the linearity of the method different 
concentration levels (5‒50 μg/ml for AZI and 4‒40 
μg/ml for OFL) were prepared from standards stock 
solutions and each solution was injected into the 
HPLC system. The peak area of the chromatogram 
obtained was noted and calibration curve was 
constructed by plotting response factor against 
concentration of drugs. Effect of small changes in the 
HPLC conditions such as change of pH 3.0 & 3.4), 
change in temperature (25°C-35°C) & change in flow 
rate (1 & 1.3 ml) was studied to evaluate robustness 
of the method while ruggedness was studied by 
performing the assay by the different analyst. The 
LOD and LOQ were determined based on the 
standard deviation of the response and the slope of 
the calibration curve. 
2. 6 Forced Degradation study  
Forced degradation studies were performed 
to evaluate the stability indicating properties 
(specificity) of the proposed method. Samples were 
subjected to stress conditions such as acid hydrolysis, 
base hydrolysis, heat or thermal, photolytic, oxidation 
and reduction. Individual drug solutions, standard 
mixture and sample solution were subjected to the 
same stress conditions to ensure the effective 
separation of degradation peaks and main peaks. 
Standard stock and sample stock solution (stock B) 
was further diluted to get the concentration 10 µg/ml 
of AZI and 8 µg/ml of OFL in individual solutions, 
their mixture and sample solution and same solutions 
were also kept as control sample.  Acid degradation 
was carried for individual drug solutions, standard 
mixture and sample solution using 10 ml of 1 N 
hydrochloric acid; alkali degradation was carried out 
in 10 ml of 0.1N sodium hydroxide. The stressed 
solutions were neutralized and then diluted with 
diluent. Oxidation degradation was performed by 
adding 10 ml of 30% H2O2 and then diluted with 
diluent. 10 ml of 10% solution of sodium bisulphate 
was added in to each flask to carry out the reduction 
study. For the thermal degradation study solid 
samples (equivalent to 500 mg of AZI & 400 mg of 
OFL) and working standards were kept in oven at 
60ºC for 24 hrs which were further diluted 
appropriately and chromatographed. Photolytic 
degradation was carried out in by exposing to UV 
radiations (1.2 million lux hr). All these solutions 
were filtered through the 0.45 μ membrane filter 
before injecting.  
 
3.0 Results and Discussion 
3.1 The Finalized Chromatographic Conditions  
Based upon system suitability parameters the 
finalized chromatographic conditions was as follows 
Column : Hypersil keystone RP C18 
Wave length : 285 nm 
Column Temp : 30ºC 
Injection Volume : 10 µl 
Run Time : 25 min 
Flow Rate : 1.2 ml / min 
Pump Mode : Isocratic 
Retention time : About 5.0 to 5.5 min (For Ofloxacin) 
  About 9.5 to 9.8 min (For Azithromycin) 
Mobile Phase : Buffer: methanol: acetonitrile (pH 3.2 
OPA) 
(0.02 M potassium dihydrogenphosphate) 
Diluent : Mobile Phase 
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3.2 Method Validation 
In system suitability the values obtained 
demonstrated the suitability of the system for the 
analysis of these drugs combination. The values for 
resolution, capacity factor, theoretical plate, HETP 
and asymmetric factor were given in Table 1. The 
values were found well within the acceptable limit. 
The method was found linear over the concentration 
range of 5‒50 μg/ml for AZI and 4‒40 μg/ml for 
OFL. The correlation coefficients (r
2
) were found to 
be 0.998 & 0.997 for AZI and OFL respectively. The 
result showed that an excellent correlation exists 
between responses and concentration of drugs (Table 
2).  The calibration curves for AZI and OFL are 
shown in Figure 3 & 4. In method precision and 
system precision studies the % RSD of the assay for 
both the drugs was found in the range of 0.26-0.85%. 
Intraday and interday analysis was performed for 
precision study. Repeatability or intraday precision 
was investigated by injecting six replicate sample 
solutions on the same day. Interday precision was 
assessed in triplicate over three consecutive days. 
The relative standard deviation (%RSD) was found to 
be well within the acceptable limit. The % RSD for 
interday and intraday study was found in the range of 
0.1 and 1.02 for AZI and OFL. The results implied 
that the method developed was precise for the 
determination. The recovery study at three different 
levels 80, 100 and 120 % was performed to assess the 
accuracy of the method. The % recovery of AZI and 
OFL was found in the range of 99.73 ‒.99.83% and 
the results of the recovery study are shown in table 3. 
The LOD and LOQ were found to be 0.00062 µg/ml 
and 0.00185µg/ml for AZI and 0.006 µg/ml and 
0.00210 µg/ml for OFL. The % RSD in robustness 
and ruggedness was found well within the acceptable 
limit (in the range of 0.0008% - 0.63%). The 
proposed method was applied for the determination 
of AZI and OFL in tablet dosage form. The % assay 
for AZI and OFL was found to be 99.74% & 99.02% 
respectively. Assay determination was carried in five 
replicates and % RSD was found less than 2% (Table 
4) and the representative chromatogram of 
formulation is shown in figure 5.   
 3.3 Forced Degradation 
Forced degradation studies were performed 
on standard drug alone, mixture of standard drugs 
and their formulation. From the degradation of these 
solutions under the same stress condition gives us an 
idea about the origin of degradant products. Peak 
purity study was performed by using purity angle and 
purity threshold parameters. Degradants did not show 
any interference with the elution of drug peaks as the 
peak purity of AZI and OFL was well within 
acceptance criteria for stressed samples. Hence, the 
method is stability indicating.  
AZI was completely degraded in 1N HCl 
and four degradants products were appeared at 0.87 
min (68.88%), 1.91 min (5.32%), 2.4 min (6.78%) 
and 3.7 min (18.90%), whereas AZI did not show any 
degradation when exposed to the stress conditions 
such as 0.1 N NaOH, 30% hydrogen peroxide 
solution, 10% sodium bisulphate and photolytic 
condition, temperature. This indicates that AZI is 
sensitive to the acid hydrolysis. On the other hand, 
OFL showed 50.01 % degradation in acidic condition 
where degradant product appeared at around 4.34 
min. In alkaline degradation OFL showed one 
degradation product peak at 4.23 min and % 
degradation was found to be 25.01 %.  OFL showed 
19.82 % and 16.4% degradation in peroxide & 
photolytic degradation respectively, but the peak of 
degradant product was not detected by the detector. 
The degradation can be confirmed from the reduced 
% assay (80.41% in peroxide & 83.81% w/w in 
photolytic degradation). OFL did not show any 
degradation in sodium bisulphate. In thermal 
degradation study OFL showed 29.13 % degradation 
which appeared at around 4.19 min. The percentage 
assay, percentage degradation at each condition along 
with their purity angle and purity threshold for AZI 
and OFL are tabulated in the table 5. 
 
Table 1: System Suitability Parameters 
Sr. 
No 
Name of drug 
Retention 
Time*(±SD) 
Area*(±SD) 
USP 
Resolution* 
(±SD) 
USP 
Tailing*(±SD) 
USP Plate 
Count*(±SD) 
1 Azithromycin 
9.735 
(±0.024) 
418968.3 
(±1234.1) 
12.54 
(±0.035) 
1.12 
(±0.008) 
214568 
(±1413.7) 
2 Ofloxacin 
5.03 
(±0.060) 
50010.1 
±(466.8) 
 
____ 
1.083 
(±0.004) 
125631 
(±223.6) 
          *Average of six determination 
 
Table 2: Linearity and Range 
Sr. 
No. 
Conc.(μg/ml) of 
Azithromycin 
Area*(± SD) Conc.(μg/ml) of 
Ofloxacin 
Area*(± SD) 
1 5 208437.31 (±833.1) 4 24392.1(±502.4 ) 
2 10 421488.02(±488.64 ) 8 50010.40(±627.42 ) 
3 20 835972.13(±256.72 ) 16 98003.73 (± 452.88) 
4 30 1186500.74(±783.82 ) 24 150761.91 (±829.15) 
5 40 1682947.06(±535.76 ) 32 212616.01 (± 681.04) 
6 50 2115445.87(±425.41 ) 40 250004.46 (± 374.82) 
 Equation of line y = 42093X‒12268  y = 6419X ‒ 1703 
Slope 42093  6419 
y-intercept ‒ 12268 ‒ 1703 
r
2
 0.998  0.997 
            *Average of six determinations 
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Table 3: Recovery Study 
Recovery 
Studies level 
80% 100% 120% 
Recovery (%) AZI OFLO AZI OFLO AZI OFLO 
Amount of Std. 
Added 
(mg) 
399.2 320.5 498.1 400 601.1 480.6 
398.7 319.7 500.7 399.5 600.4 478.9 
401.4 319.4 500.9 400.8 600.2 479.6 
Amount 
Recovered 
(mg) 
398.1 318.8 497.8 398.52 600.66 479.98 
398.5 319.5 499.6 398.26 599.89 478.84 
400.5 318.8 500.74 400.32 598.69 478.26 
 
% Recovery 
 
99.72 99.46 99.93 99.63 99.92 99.87 
99.94 99.93 99.78 99.68 99.91 99.98 
99.77 99.81 99.96 99.88 99.74 99.72 
Mean 
Recovery 
99.81 99.73 99.89 99.73 99.86 99.85 
SD 0.1181 0.2421 0.1012 0.130 0.0997 0.1337 
%RSD 0.1183 0.2428 0.1013 0.131 0.099 0.1339 
 
Table 4: Assay of marketed formulation 
Brand Name 
AZITHROMYCIN OFLOXACIN 
Label Claim (mg) % Assay 
Label Claim 
(mg) 
% Assay 
Zithium-O 
(AZI 500 
mg+ OFL 
400 mg) 
500 99.7 400 99.5 
500 99.8 400 98.9 
500 99.8 400 99.2 
500 99.6 400 98.1 
500 99.8 400 99.4 
Mean 
 
99.74 
 
99.02 
SD 0.0894 0.5630 
%RSD 0.0896 0.5685 
 
Table 5: Forced Degradation Study 
 Peak Purity for 
Azithromycin peak 
Peak Purity for  
Ofloxacin 
Sr. 
No 
Condition % Assay 
of 
Azithromycin 
% 
degradation 
w.r.t. 
Control 
% Assay 
Of 
Ofloxacin 
% 
degradation 
w.r.t. 
 Control 
Purity 
Angle 
Purity 
Threshold 
Purity 
Angle 
Purity 
Threshold 
1 Control 
Sample 100.15  --- 100.23 --- 0.176 1.163 0.185 1.077 
2 Acid 
degradation 0.00 100.00 50.22 50.01 0.34 1.463 0.191 1.082 
3 Base 
degradation 99.93 0.22 75.22 25.01 0.317 1.288 0.156 1.079 
4 Peroxide 
degradation 99.83 0.32 80.41 19.82 0.346 1.219 0.207 1.103 
5 Reduction 
degradation 99.68 0.47 100.23 0.00 0.314 1.239 0.184 1.075 
6 Thermal 
degradation 99.80 0.35 71.10 29.13 0.315 1.261 0.166 1.072 
7 Photolytic 
degradation 99.78 0.37 83.81 16.42 0.385 1.233 0.173 1.081 
 
Figure 3: Calibration Curve of Azithromycin 
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Figure 4: Calibration Curve of Ofloxacin 
 
           Figure 5: Representative chromatograms standard mixture 
 
4.0 Conclusion 
A simple and precise stability indicating 
HPLC method has been developed for estimation of 
AZI and OFL in tablet dosage form. The %RSD 
values in precision, recovery studies, robustness and 
ruggedness studies was found less  than 2.0% which 
indicates that the method is precise, accurate and 
robust. The LOD and LOQ were found to be 0.00062 
µg/ml and 0.00185µg/ml for AZI and 0.006 µg/ml 
and 0.00210 µg/ml for OFL indicates that the method 
is sensitive for the determination of lower 
concentration of the both the drugs. The % assay was 
found to be well within the acceptable limit. In 
degradation studies it was found that AZI was more 
sensitive to acidic degradation, while OFL showed 
degradation in acidic, alkali, peroxide, photolytic 
thermal conditions. The peaks of the degradants in 
each condition were well separated from main peaks. 
Purity plot confirmed that there is no interference of 
any degradants at the retention time of the main 
peaks indicates that the developed method is stability 
indicating. The proposed method can be used as an 
alternative method for the analysis of AZI and OFL 
in its dosage forms. 
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